A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma.
Gastric Neoplasms|Pancreatic Neoplasms
DRUG: ASG-5ME
Incidence of adverse events and laboratory abnormalities, Through 1 month after last dose
Best clinical response, Every 2 months|Overall and progression-free survival, Every month until death or study closure|Concentrations of ASG-5ME and metabolites in blood, Through 1 month after last dose|Incidence of antitherapeutic antibodies in blood, Through 1 month after last dose
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma, and to evaluate safety and tolerability in patients with relapsed or refractory gastric adenocarcinoma.